ArticleFrontiers in pharmacology2025
Integrated gut microbiota and metabolomics analysis reveals the antitumor effects of ergosta-4,6,8(14),22-tetraen-3-one purified from the medicinal fungus pholiota adiposa in tumor-bearing mice.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the antitumour mechanism of ergosta-4,6,8(14),22-tetraen-3-one (ETO), extracted from Pholiota adiposa, in H22 tumour-bearing mice through integrated metabolomics and gut microbiota systems analysis. Methods: After establishing the H22 tumor mouse model, we performed serum metabolomics through nontargeted UHPLC-HRMS and conducted gut microbiota profiling. Result: ETO exhibited significant antitumor effects, with tumor inhibition rates of 59.74% (low dose) and 76.10% (high dose).Untargeted metabolomics revealed that molecules downstream of the tricarboxylic acid cycle, arachidonic acid and linoleic acid were upregulated. Gut microbiota analysis revealed ETO-mediated enrichment of beneficial bacteria (Firmicutes and Lactobacillus) and suppression of the harmful bacterial species Bartonella. Integrative analysis demonstrated a negative correlation between indole-3-acetonitrile and Bartonella. Conclusion: ETO can inhibit the growth of tumor cells, and its effect on liver and kidney damage is less than that of CTX. Linoleate, and L-tryptophan emerged as potential therapeutic targets, while Firmicutes and Lactobacillus enrichment suggests gut microbiota-mediated antitumor activity, providing novel insights for hepatocellular carcinoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.